Seminars in Hematology
Volume 45 , Pages S22-S24 , July 2008

Arsenic and Old Lace: Novel Approaches in Elderly Patients With Acute Myeloid Leukemia

  • Gail J. Roboz

      Affiliations

    • Corresponding Author InformationAddress correspondence to Gail J. Roboz, MD, Associate Professor of Medicine, Weill Medical College of Cornell University, 520 E 70th St, Starr 340A, New York, NY 10021

References 

  1. Osler W. On the use of arsenic in certain forms of anaemia. The Therapeutic Gazette 3rd Series. 1886;II:741–746
  2. Haller JS. Therapeutic mule: The use of arsenic in the nineteenth century materia medica. Pharm Hist. 1975;17:87–100
  3. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893–3903
  4. Rojewski MT, Korper S, Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: From bench to bedside. Leuk Lymphoma. 2004;45:2387–2401
  5. Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: Induction of apoptosis and inhibition of proliferation. Br J Haematol. 2002;116:555–563
  6. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000;96:1525–1530
  7. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124
  8. Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res. 2004;28:909–919
  9. Douer D, Ramezani L, Watkins K, Louie R, Tallman MS. Durable molecular remission in two acute promyelocytic leukemia (APL) patients treated with arsenic trioxide at first molecular relapse. Blood. 2005;106:525a;(abstr)
  10. Study of low-dose cytarabine in combination with arsenic trioxide, compared with low-dose cytarabine alone, for the treatment of elderly patients with acute myeloid leukemia. http://clinicaltrials.gov/ct2/show/NCT00513305Accessed January 22, 2008

 STATEMENT OF CONFLICT OF INTEREST: Research support/Principal Investigator: Cephalon; Consultant/Scientific Advisory Board: Cephalon.

PII: S0037-1963(08)00121-2

doi: 10.1053/j.seminhematol.2008.07.005

Seminars in Hematology
Volume 45 , Pages S22-S24 , July 2008

Article Tools